The definition of the high level system requirements has been peformed for the two different investigational devices that will be used for the evaluation of the perovskite direct X-ray detection technology for cardiovascular disease (CCVD) and chronic obstructive pulmonary disease (COPD).
The two first milestones of the project have been passed:
- For the powder sintering route, the frontplane process has been demonstrated on 5x5 cm² size devices
- For the solution-process route, a growth reactor developed for 5x5 cm² active matrixes is operational.
For the powder sintering approach, image measurements on medium size devices (5x5 cm²) show performance in spatial resolution, linearity, sensitivity, signal lag and long term stability which allow to assess that perovskite detectors have the potential to outperform the existing direct conversion detectors based on amorphous selenium.
For the solution process approach, freestanding single devices have been achieved for advanced characterization.
Advanced electronic characterization methods such as impedance spectroscopy and transient techniques have been used to measure the electrical response of single diode devices from both processes. This allowed to gain fundamental knowledge on the connection between device architecture (absorbing perovskite layer structure, contacting electrodes...) and operational mechanisms and device physics of X-ray detectors. These results have been described into two publications.
The development and the sourcing of detector components, especially the key components corresponding to the TFT arrays for the different imaging test vehicles, have been achieved for further steps in the detectors maunfacturing process.
For phase contrast imaging purpose, physical limits of spatial resolution on perovskite layers have been calculated and characterization of first samples have been conducted.
